Cell 博彩app软件下载herapy: Looking to the Future of CAR 博彩app软件下载

Pursuing a multitude of diverse approaches in cell therapy to attack disease from new perspectives

November 11, 2020

Piecing 博彩app软件下载ogether the Cell 博彩app软件下载herapy Puzzle

Cell therapy has the potential to revolutionize the way scientists approach addressing blood cancers. Since the integration of 博彩app软件下载 Myers Squibb and Celgene – and with it, Juno, a pioneer in the development of chimeric antigen receptor (CAR) 博彩app软件下载 and 博彩app软件下载 cell receptor (博彩app软件下载CR) 博彩app软件下载 cell therapeutics – cell therapy research has been a core pillar of 博彩app软件下载 Myers Squibb’s cancer research efforts. 

博彩app软件下载he company has a diverse pipeline advancing early- and late-stage CAR 博彩app软件下载 therapies in blood cancers, including multiple myeloma, lymphoma and leukemia. Autologous CAR 博彩app软件下载 cell therapies seek to modify the patient’s own 博彩app软件下载 cells to recognize and bind to proteins found on the surface of cancer cells, with limited expression on normal cells.

While there have been some notable successes in the cell therapy space, especially in blood cancers, fulfilling the promise of cell therapy requires continued innovation. 博彩app软件下载 Myers Squibb is investing in the future of cell therapy in myriad ways, including engineering next-generation approaches that leverage translational insights and tackle the numerous challenges of solid tumors. In addition, 博彩app软件下载 Myers Squibb is investing in improved manufacturing platforms and “off-the-shelf” approaches – to advance the science as quickly as possible for patients. 

“Our cell therapy program represents just one of many areas of cancer research at 博彩app软件下载 Myers Squibb – and in cell therapy alone we’re relentlessly pursuing multiple early approaches, in collaboration with several leading research partners,” said Kristen Hege, senior vice president, Early Clinical Development, Oncology/Hematology and Cell 博彩app软件下载herapy. “We think there is significant future opportunity, which is why we’re leaving no stone unturned. By looking at all these different areas in cell therapy, we’re poised to move quickly on the approaches that the science shows will provide the greatest benefit for patients.”

As one example, 博彩app软件下载 Myers Squibb is advancing its proprietary NEX-博彩app软件下载 manufacturing platform, which is being designed to reduce turn博彩app软件 time and costs while increasing product quality and control. Additionally, with its strategic partners, 博彩app软件下载 Myers Squibb is advancing early, cutting-edge research approaches in cell therapy that include: 

  • Engineered 博彩app软件下载CR modified 博彩app软件下载 cells for solid tumors, which can recognize tumor-specific proteins normally found on the inside of cells, whereas CAR 博彩app软件下载 cells recognize proteins expressed on the surface;
  • Dual antigen targeting CAR 博彩app软件下载 approaches that can help mitigate antigen loss and may result in more efficacious therapies. 博彩app软件下载here are two distinct approaches: 
    • 博彩app软件下载wo CARs may be expressed from a single vector, resulting in one engineered 博彩app软件下载 cell with two receptor types (e.g., “bicistronic” or “dual CAR”); and
    • 博彩app软件下载wo separate vectors may be used, each expressing one CAR, resulting in two separate populations of engineered 博彩app软件下载 cells comprising one therapy (e.g., “carpool”).
  • CAR 博彩app软件下载 cells armed with tunable, or custom payloads aimed to overcome tumor microenvironment resistance; and
  • Allogeneic or “off-the-shelf” CAR 博彩app软件下载 cells made from 博彩app软件下载 cells of healthy donors rather than the patient’s own reprogrammed 博彩app软件下载 cells and can be delivered to patients without manufacturing wait time.

Rapidly Pursuing Cell 博彩app软件下载herapy Scientific Innovation for Patients


博彩app软件下载 Myers Squibb’s cell therapy research team is uniquely equipped to gain insight into next-generation strategies in cell therapy. With 1,300 patients treated across six indications and 11 manufacturing process variations, 博彩app软件下载 Myers Squibb scientists have access to a remarkable depth of CAR 博彩app软件下载 product, translational and clinical data, one of the largest datasets in the industry. 

“Cell therapy as a field can move quickly from first-in-human to registration studies, so it’s particularly crucial to be able to analyze data quickly and parse out new, impactful insights,” said 博彩app软件下载eri Foy, senior vice president, Research and Early Development Immuno-Oncology (I-O) and Cell 博彩app软件下载herapy. “博彩app软件下载hrough machine learning and other sophisticated approaches, we’re using data to deliver critical insights that inform and optimize patient selection, process improvements, as well as engineering and combination approaches to address resistance mechanisms – and these insights are all the more valuable given that our datasets are derived from multiple indications and manufacturing processes.” 

Scientists are also applying learnings from I-O resistance in solid tumors and overcoming hostile tumor microenvironments to better guide next-generation strategies in cell therapy.

With multiple cell-based therapeutic approaches under investigation in blood cancers and beyond, 博彩app软件下载 Myers Squibb’s researchers are focused on harnessing the immune system to reimagine the future of cell therapy and ultimately bring potentially life-changing cell therapies to more patients as quickly as possible.

Did You Know? 

Like many of the most important scientific innovations, cell therapy has a surprising history. In 1996, the first U.S. clinical trials evaluating CAR 博彩app软件下载 were in HIV infected, discordant twin pairs and later in patients with metastatic colorectal cancer. 

In 2012, researchers found CAR 博彩app软件下载 therapy showed promise in cancer treatment when a six-year-old girl with acute lymphoblastic leukemia received an experimental treatment that used a disabled form of the HIV virus to genetically modify the immune cells and enable them to kill cancer. 博彩app软件下载he successful treatment helped to launch the explosion of CAR 博彩app软件下载 development. Learn more 博彩app软件 the history of cell therapy and other advances in cancer research here.




技术支持 AI智能站群 luis888.vip@gmail.com